应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
DWTX DOGWOOD THERAPEUTICS INC
已收盘 10-29 16:00:00 EDT
1.23
-0.01
-0.81%
盘后
1.19
-0.04
-3.25%
19:49 EDT
最高
1.38
最低
1.19
成交量
9.59万
今开
1.24
昨收
1.24
日振幅
15.31%
总市值
4,181万
流通市值
714.62万
总股本
3,399万
成交额
11.88万
换手率
1.65%
流通股本
580.99万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Dogwood完成Halneuron® 2B期化疗诱发神经病变试验首批200名患者入组;关键数据预计2026年秋季公布
美股速递 · 07-20
Dogwood完成Halneuron® 2B期化疗诱发神经病变试验首批200名患者入组;关键数据预计2026年秋季公布
Dogwood Therapeutics任命奥博资本风险合伙人Iain Dukes为科学顾问委员会主席
美股速递 · 06-30
Dogwood Therapeutics任命奥博资本风险合伙人Iain Dukes为科学顾问委员会主席
Dogwood Therapeutics Inc - 扩展试验数据将支持2027年上半年三期项目向FDA提交申请
美股速递 · 05-18
Dogwood Therapeutics Inc - 扩展试验数据将支持2027年上半年三期项目向FDA提交申请
Dogwood Therapeutics 2026年第一季度净亏损500万美元,合每股0.15美元
美股速递 · 05-14
Dogwood Therapeutics 2026年第一季度净亏损500万美元,合每股0.15美元
Dogwood Therapeutics 宣布达成历史抗病毒资产合作,潜在价值高达1亿美元
美股速递 · 05-14
Dogwood Therapeutics 宣布达成历史抗病毒资产合作,潜在价值高达1亿美元
Dogwood Therapeutics 达成抗病毒资产全球开发与商业化合作 潜在价值高达1亿美元
美股速递 · 04-23
Dogwood Therapeutics 达成抗病毒资产全球开发与商业化合作 潜在价值高达1亿美元
加载更多
公司概况
公司名称:
DOGWOOD THERAPEUTICS INC
所属市场:
NASDAQ
上市日期:
--
主营业务:
Dogwood Therapeutics, Inc.最初于2012年2月28日在阿拉巴马州成立,后来改为内华达州公司。Dogwood是一家尚未盈利的生物制药公司,处于研发阶段,专注于发现和开发治疗疼痛和神经病变的新药。公司研发管线主要集中于慢性神经性疼痛和神经病变,其核心产品是Halneuron Nav1.7调节剂项目。该项目是一种专有的非阿片类镇痛方法,通过靶向电压门控钠通道Nav1.7来减轻疼痛。
发行价格:
--
{"stockData":{"symbol":"DWTX","market":"US","secType":"STK","nameCN":"DOGWOOD THERAPEUTICS INC","latestPrice":1.23,"timestamp":1793304000000,"preClose":1.24,"halted":0,"volume":95930,"hourTrading":{"tag":"盘后","latestPrice":1.19,"preClose":1.23,"latestTime":"19:49 EDT","volume":1080,"amount":1286.59,"timestamp":1793317781333,"change":-0.04,"changeRate":-0.03252,"amplitude":0.03252},"delay":0,"changeRate":-0.008064516129032265,"floatShares":5809900,"shares":33992600,"eps":-8.9478,"marketStatus":"已收盘","change":-0.01,"latestTime":"10-29 16:00:00 EDT","open":1.24,"high":1.3799,"low":1.19,"amount":118819.224162,"amplitude":0.153145,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.9478,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793347200000},"marketStatusCode":5,"adr":0,"listingDate":1608181200000,"exchange":"NASDAQ","adjPreClose":1.24,"preHourTrading":{"tag":"盘前","latestPrice":1.25,"preClose":1.24,"latestTime":"09:28 EDT","volume":282,"amount":349.9350126,"timestamp":1793280480131,"change":0.01,"changeRate":0.008065,"amplitude":0.008065},"postHourTrading":{"tag":"盘后","latestPrice":1.19,"preClose":1.23,"latestTime":"19:49 EDT","volume":1080,"amount":1286.59,"timestamp":1793317781333,"change":-0.04,"changeRate":-0.03252,"amplitude":0.03252},"volumeRatio":2.24672},"requestUrl":"/m/hq/s/DWTX","defaultTab":"news","newsList":[{"id":"1113001000","title":"Dogwood完成Halneuron® 2B期化疗诱发神经病变试验首批200名患者入组;关键数据预计2026年秋季公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1113001000","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113001000?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:32","pubTimestamp":1784550725,"startTime":"0","endTime":"0","summary":"在针对化疗诱发神经病变的Halneuron® 2B期临床试验中,Dogwood Therapeutics已成功完成首批200名患者的入组工作。这项持续进行的试验预计将在2026年秋季获得关键性数据结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153907881","title":"Dogwood Therapeutics任命奥博资本风险合伙人Iain Dukes为科学顾问委员会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=1153907881","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153907881?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:46","pubTimestamp":1782823577,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc. 宣布了一项重要人事任命,Iain Dukes 将担任其科学顾问委员会主席一职。Dukes 先生目前是知名投资机构奥博资本的风险合伙人,他在生物技术和生命科学领域拥有深厚的专业背景与丰富的行业经验。此次任命旨在进一步加强 Dogwood Therapeutics 的科学战略指导与研发能力。公司期望借助 Dukes 先生在药物开发、企业战略及投资方面的专长,加速其治疗管线的推进,并为未来的科学决策提供关键洞见。Dukes 先生的加入,预计将为 Dogwood Therapeutics 带来更广阔的行业视野和战略资源。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137042063","title":"Dogwood Therapeutics Inc - 扩展试验数据将支持2027年上半年三期项目向FDA提交申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1137042063","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137042063?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:46","pubTimestamp":1779108396,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc 宣布,其扩展试验数据将为公司在2027年上半年向美国食品药品监督管理局(FDA)提交三期项目申请提供关键支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159504779","title":"Dogwood Therapeutics 2026年第一季度净亏损500万美元,合每股0.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159504779","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159504779?lang=zh_cn&edition=full","pubTime":"2026-05-14 20:35","pubTimestamp":1778762111,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc公布2026年第一季度财务业绩,归属于普通股股东的净亏损为500万美元,摊薄后每股亏损0.15美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141459489","title":"Dogwood Therapeutics 宣布达成历史抗病毒资产合作,潜在价值高达1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1141459489","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141459489?lang=zh_cn&edition=full","pubTime":"2026-05-14 20:34","pubTimestamp":1778762087,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc 宣布,已就一批历史抗病毒资产达成一项合作协议。该合作潜在价值最高可达1亿美元,标志着公司在盘活非核心资产、挖掘其潜在价值方面取得了重要进展。此次合作旨在通过外部专业力量,进一步开发这些资产的商业潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191715043","title":"Dogwood Therapeutics 达成抗病毒资产全球开发与商业化合作 潜在价值高达1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191715043","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191715043?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:01","pubTimestamp":1776949299,"startTime":"0","endTime":"0","summary":"DOGWOOD THERAPEUTICS INC 近日宣布,已就旗下抗病毒资产达成一项全球范围内的开发与商业化战略合作伙伴关系。此次合作蕴含巨大潜力,其总价值有望攀升至1亿美元,标志着公司在抗病毒治疗领域迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.dwtx.com;www.dwtx.com","stockEarnings":[{"period":"1week","weight":0.0598},{"period":"1month","weight":-0.0882},{"period":"3month","weight":-0.2152},{"period":"6month","weight":-0.1507},{"period":"1year","weight":-0.8025},{"period":"ytd","weight":-0.7019}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0088},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.0717},{"period":"1year","weight":0.1241},{"period":"ytd","weight":0.1326}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Dogwood Therapeutics, Inc.最初于2012年2月28日在阿拉巴马州成立,后来改为内华达州公司。Dogwood是一家尚未盈利的生物制药公司,处于研发阶段,专注于发现和开发治疗疼痛和神经病变的新药。公司研发管线主要集中于慢性神经性疼痛和神经病变,其核心产品是Halneuron Nav1.7调节剂项目。该项目是一种专有的非阿片类镇痛方法,通过靶向电压门控钠通道Nav1.7来减轻疼痛。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.643793},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.153661},{"month":3,"riseRate":0.5,"avgChangeRate":0.00331},{"month":4,"riseRate":0.333333,"avgChangeRate":0.090085},{"month":5,"riseRate":0.5,"avgChangeRate":0.166607},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.023497},{"month":7,"riseRate":0.666667,"avgChangeRate":0.16521},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007149},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.184666},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.175201},{"month":11,"riseRate":0.8,"avgChangeRate":-0.028445},{"month":12,"riseRate":0.4,"avgChangeRate":-0.112321}],"exchange":"NASDAQ","name":"DOGWOOD THERAPEUTICS INC","nameEN":"DOGWOOD THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"DOGWOOD THERAPEUTICS INC(DWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供DOGWOOD THERAPEUTICS INC(DWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"DOGWOOD THERAPEUTICS INC,DWTX,DOGWOOD THERAPEUTICS INC股票,DOGWOOD THERAPEUTICS INC股票老虎,DOGWOOD THERAPEUTICS INC股票老虎国际,DOGWOOD THERAPEUTICS INC行情,DOGWOOD THERAPEUTICS INC股票行情,DOGWOOD THERAPEUTICS INC股价,DOGWOOD THERAPEUTICS INC股市,DOGWOOD THERAPEUTICS INC股票价格,DOGWOOD THERAPEUTICS INC股票交易,DOGWOOD THERAPEUTICS INC股票购买,DOGWOOD THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"DOGWOOD THERAPEUTICS INC(DWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供DOGWOOD THERAPEUTICS INC(DWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}